Skip to content
Sign in

IDXX · NASDAQ

IDEXX Laboratories (IDXX) Stock Price & Fundamentals

$708.68+1.26%+$8.84End-of-day price as of Oct 9, 2026

IDEXX Laboratories (IDXX) closed at $708.68 on Oct 9, 2026, up 1.26% from the previous close of $699.84.

Share price, past year

1Y +10.77%

52-week range $594.91 – $708.68. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$708.68
Sep 30, 2026$687.81
Aug 31, 2026$656.96
Jul 31, 2026$640.96
Jun 30, 2026$640.06
May 29, 2026$603.94
Apr 30, 2026$617.43
Mar 31, 2026$596.72
Feb 27, 2026$606.09
Jan 30, 2026$603.47
Dec 31, 2025$641.51
Nov 28, 2025$647.78
Oct 31, 2025$670.82

Key statistics

Market cap
$55.90B
P/E (TTM)
49.8
EPS (TTM)
$14.23
Revenue (TTM)
$4.55B
Net income (TTM)
$1.14B
Shares outstanding
78.9M
Dividend yield
—
52-week range
$594.91 – $708.68

IDEXX Laboratories's market cap is $55.90B, based on a share price of $708.68 and 78.9M shares outstanding as of Jun 30, 2026.

Financials

IDEXX Laboratories reported revenue of $4.30B for fiscal 2025, up 10.42% from fiscal 2024.

IDEXX Laboratories earned net income of $1.06B in fiscal 2025, a net margin of 24.6%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
IDEXX Laboratories annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$4.30B+10.4%$1.06B24.6%$13.08$1.06B
FY2024ended Dec 31, 2024$3.90B+6.5%$887.87M22.8%$10.67$808.08M
FY2023ended Dec 31, 2023$3.66B+8.7%$845.04M23.1%$10.06$772.88M
FY2022ended Dec 31, 2022$3.37B+4.7%$679.09M20.2%$8.03$394.15M
FY2021ended Dec 31, 2021$3.22B+18.8%$744.85M23.2%$8.60$636.00M
FY2020ended Dec 31, 2020$2.71B+12.5%$581.78M21.5%$6.71$541.11M
FY2019ended Dec 31, 2019$2.41B+8.8%$427.72M17.8%$4.89$304.19M
FY2018ended Dec 31, 2018$2.21B+12.4%$377.03M17.0%$4.26$284.33M
FY2017ended Dec 31, 2017$1.97B+10.9%$263.14M13.4%$2.94$298.89M
FY2016ended Dec 31, 2016$1.78B—$222.05M12.5%$2.44—
IDEXX Laboratories quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$1.22B$338.41M$4.27
Q1 FY2026ended Mar 31, 2026$1.14B$278.45M$3.47
Q4 FY2025ended Dec 31, 2025$1.09B$248.19M$3.09
Q3 FY2025ended Sep 30, 2025$1.11B$274.61M$3.40
Q2 FY2025ended Jun 30, 2025$1.11B$293.99M$3.63
Q1 FY2025ended Mar 31, 2025$998.43M$242.68M$2.96
Q4 FY2024ended Dec 31, 2024$954.29M$216.15M$2.62
Q3 FY2024ended Sep 30, 2024$975.54M$232.84M$2.80

Company profile

Name
IDEXX Laboratories, Inc.
Ticker
IDXX
Exchange
NASDAQ
Industry (SEC SIC)
In Vitro & In Vivo Diagnostic Substances
Headquarters
One Idexx Drive, Westbrook, ME 04092-2041
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0000874716

Recent SEC filings

Frequently asked questions

What is IDEXX Laboratories's stock price?

IDEXX Laboratories (IDXX) closed at $708.68 on Oct 9, 2026, up 1.26% from the previous close of $699.84.

What is IDEXX Laboratories's market cap?

IDEXX Laboratories's market cap is $55.90B, based on a share price of $708.68 and 78.9M shares outstanding as of Jun 30, 2026.

How much revenue does IDEXX Laboratories make?

IDEXX Laboratories reported revenue of $4.30B for fiscal 2025, up 10.42% from fiscal 2024.

What is IDXX's P/E ratio?

IDEXX Laboratories's price-to-earnings ratio is 49.8, based on trailing twelve-month diluted EPS of $14.23.

Does IDEXX Laboratories pay a dividend?

IDEXX Laboratories's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from IDEXX Laboratories, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures